| I-08 Rubin Lubomirov Population pharmacokinetic-based interspecies allometric scaling and prediction of first-in-human (FIH) pharmacokinetics of a new anticancer agent Wednesday 10:30-12:00 |
| I-11 Sreenath M Krishnan Influence of the number of tumor size measurements on model-derived tumor size metrics and prediction of survival Wednesday 10:30-12:00 |
| I-19 Emma Martin Using mixed effects modelling improves detection of drug-gene interactions in mouse trials Wednesday 10:30-12:00 |
| I-35 Sean Oosterholt PKPD modelling of MYCN-inhibition in vitro and in vivo in a mouse model of neuroblastoma Wednesday 10:30-12:00 |
| I-43 Sophie Peigné How to handle non-linearity in absorption: a case study in oncology Wednesday 10:30-12:00 |
| I-45 Belén Pérez Solans Modelling tumour growth and progression free survival of breast cancer patients treated with neoadjuvant therapy Wednesday 10:30-12:00 |
| II-21 Ajit Suri Population Pharmacokinetic Modeling of Brentuximab Vedotin, a CD30-Directed Antibody-Drug Conjugate, and its cytotoxic payload (MMAE) in Patients With Various Hematological Malignancies Wednesday 15:10-16:30 |
| II-25 Adrien Tessier Investigating the PK/PD relationship of a new pro-apoptotic drug through tumor growth inhibition modelling in NUDE rats Wednesday 15:10-16:30 |
| II-29 Elena Tosca A PK/PD model for tumor-in-host growth kinetics following administration of an antiangiogenic agent given alone or in combination regimens Wednesday 15:10-16:30 |
| II-46 Marc Vandemeulebroecke Multi-state modeling and simulation of patient trajectories after allogeneic hematopoietic stem cell transplantation (allo-HSCT) to inform drug development Wednesday 15:10-16:30 |
| II-55 Sebastian Wicha The purpose determines the predictive performance: Comparison of four population pharmacokinetic models of methotrexate. Wednesday 15:10-16:30 |
| II-57 Francis Williams Ojara Examining the relationship between paclitaxel exposure and peripheral neuropathy in non-small cell lung cancer Wednesday 15:10-16:30 |
| II-60 Gudrun Wuerthwein Population Pharmacokinetics to model the time-varying clearance of the PEGylated asparaginase Oncaspar® in children with ALL Wednesday 15:10-16:30 |
| II-62 Joao Paulo Ximenez Population pharmacokinetic of tamoxifen and its metabolites in breast cancer patients Wednesday 15:10-16:30 |
| III-10 María García-Cremades Mechanistic multi-scale systems pharmacokinetics model applied for the anticancer drug gemcitabine in pancreatic cancer Thursday 09:50-11:20 |
| III-36 Itziar Irurzun-Arana Population PD modelling of circulating biomarkers in patients with melanoma treated with interferon alpha2b Thursday 09:50-11:20 |
| III-42 Martin Johnson Exposure response relationship for interstitial lung disease (ILD) events following osimertinib treatment Thursday 09:50-11:20 |
| III-45 Matts Kågedal Herceptin in HER2-positive Gastric Cancer: Evaluation of Exposure-Response with Two Dose Levels. Thursday 09:50-11:20 |
| III-51 Lena Klopp-Schulze Exploring and explaining variability in tamoxifen and endoxifen pharmacokinetics in breast cancer patients: A pooled analysis Thursday 09:50-11:20 |
| III-57 Yuri Kosinsky Radiation and anti-PD-L1 treatment combinations: Immune cell responses and dose scheduling optimization using a joint experimental and systems modeling approach Thursday 09:50-11:20 |
| III-59 Anu Shilpa Krishnatry Population pharmacokinetics and pharmacodynamics of GSK525762 in patients with solid tumors Thursday 09:50-11:20 |
| III-63 Silvia Maria Lavezzi Modelling of rituximab clearance reduction due to ibrutinib co-administration Thursday 09:50-11:20 |
| IV-06 Usman Arshad Population pharmacokinetic model of mitotane enzyme autoinduction in adrenocortical carcinoma patients Thursday 14:45-16:15 |
| IV-14 Guillaume Baneyx Population pharmacokinetic modeling of pazopanib in healthy volunteers and patients with advanced renal cell carcinoma. Thursday 14:45-16:15 |
| IV-17 Brendan Bender A Mechanism-Based Model of Tumor Quiescence and Resistance in HER2-Negative Metastatic Breast Cancer in Patients Receiving Docetaxel or Paclitaxel Thursday 14:45-16:15 |
| IV-19 Aliénor Bergès Dose-exposure-response model between an ATR inhibitor and peripheral monocytes Thursday 14:45-16:15 |
| IV-28 Núria Buil Bruna Predicting myelosuppression from phase I data: Which model should we use? Thursday 14:45-16:15 |
| IV-42 S. Y. Amy Cheung Optimising Phase 1 oncology dosing schedule of an ATR inhibitor in real time using a model informed approach to predict myelosuppression Thursday 14:45-16:15 |
| IV-55 Aurelia de Vries Schultink Modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens. Thursday 14:45-16:15 |
| IV-61 Solène Desmée Mechanistic joint modelling for longitudinal PSA and survival data in advanced metastatic prostate cancer Thursday 14:45-16:15 |
